Coeptis Therapeutics Holdings, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a COEP research report →
Price Chart
About the company
Coeptis Therapeutics Holdings, Inc. , together with its subsidiaries, operates as a biopharmaceutical and technology company. The company is developing cell therapy platforms for cancer, autoimmune, and infectious diseases.
- CEO
- David Mehalick
- IPO
- 2020
- Employees
- 6
- HQ
- Wexford, PA, US
Get TickerSpark's AI analysis on COEP
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $38.62M
- P/E
- -0.97
- PEG
- -0.01
- P/S
- 32.88
- P/B
- 0.65
- EV/EBITDA
- -3.97
- Div Yield
- 0.00%
- Gross Margin
- -429.84%
- Op Margin
- -779.25%
- Net Margin
- -785.07%
- ROE
- -47.98%
- ROIC
- -16.45%
Latest fiscal year · YoY change
- Revenue
- $1.36M+0.0%
- Gross Profit
- $1.18M+0.0%
- Op Income
- $-13,043,498
- Net Income
- $-11,917,015-11.6%
- EPS
- $-2.81+50.3%
- OCF Growth
- -29.4%
- FCF Growth
- -29.4%
- 52W High
- $21.41
- 52W Low
- $6.80
- 50D MA
- $12.25
- 200D MA
- $13.72
- Beta
- -0.43
- RSI (14)
- 72
- Avg Volume
- 50.88K
No earnings-call transcripts are available for COEP yet.
- Free Float
- 85.9%
- Shares Outstanding
- 3.51M
- Float Shares
- 3.02M
of shares held by institutions
1 13F filers
Buy/sell ratio 0.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Held by 1 ETFs
Biggest fund positions in COEP by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Apr 24, 26 | BSG Series CM, LLC | other | 0 |
| Feb 11, 26 | Cogley Brian | other | 12,500 |
| Feb 11, 26 | Cogley Brian | other | 10,000 |
| Feb 11, 26 | Deschamps Philippe | other | 5,700 |
| Feb 11, 26 | Deschamps Philippe | other | 3,250 |
| Feb 11, 26 | Calise Chris | other | 3,250 |
| Feb 11, 26 | Calise Chris | other | 5,700 |
| Feb 11, 26 | Mehalick David | other | 148,875 |
| Feb 11, 26 | Mehalick David | other | 51,250 |
| Feb 11, 26 | Cochran Christopher P. | other | 5,700 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our COEP coverage
Recent articles, reports, and earnings notes.
No research on COEP yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate COEP report →Z Squared Announces Completion of Business Combination with Coeptis Therapeutics and Listing on the Nasdaq Global Market
prnewswire.com · Apr 24
Coeptis Announces Approval of Z Squared Inc.'s Nasdaq Listing Application
globenewswire.com · Apr 7
Coeptis Receives Shareholder Approval Towards Z Squared Merger
globenewswire.com · Feb 5
Coeptis Therapeutics S-4 Declared Effective by SEC, Proxy Mailing Begins in Anticipation of the Merger Transaction with Z Squared
globenewswire.com · Jan 6
Coeptis Therapeutics (NASDAQ:COEP) Stock Price Down 3.6% – Time to Sell?
defenseworld.net · Dec 11
Vanderbilt Report: Coeptis Shows How Biotech Can Fund Itself While Innovating
globenewswire.com · Sep 23
Coeptis (COEP) Extinguishes Convertible Note with YA II PN, Ltd
globenewswire.com · Jul 22
Coeptis (COEP) Announces Filing of Registration Statement on Form S-4 with SEC in Connection with Proposed Transaction with Z Squared
globenewswire.com · Jun 26
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.